SS Innovations International (NASDAQ: SSII) has reported significant growth in the adoption of its SSi Mantra surgical robotic system, with cumulative procedures reaching 14,103 as of September 8, 2026, a 79% increase from 7,885 at the end of 2025. The company also noted that its installed base grew to 238 systems, up 42% from 168 at year-end, now spanning 12 countries following recent launches in Colombia and Sri Lanka. This expansion underscores the company's ability to penetrate new markets and drive adoption of its robotic surgery platform.
The growth in procedures and installations is a key indicator of SSi Mantra's clinical acceptance and commercial traction. With approximately 1,500 physicians trained on the system, the company is building a robust user base that could lead to further procedure growth and reinforce its competitive position in the global surgical robotics market. The expansion into pediatric applications, including a robotic kidney procedure performed on a 45-day-old infant in India using 5-millimeter instruments, highlights the system's versatility and potential to address a broader range of surgical needs. Such capabilities may open additional market opportunities and demonstrate the technology's safety and efficacy in delicate procedures.
Moreover, the company reported 188 cumulative robotic telesurgeries as of August 31, 2026, along with long-distance procedures connecting surgeons and patients across countries. This tele-surgery capability could be particularly impactful in regions with limited access to specialized surgical expertise, allowing remote surgeons to perform complex operations. It also positions SS Innovations as a potential leader in the emerging field of remote robotic surgery, which could drive further adoption and partnerships.
Looking ahead, SS Innovations anticipates FDA review of its 510(k) submission by the end of Q1 2027 and believes EU CE marking for SSi Mantra could be obtained by the end of 2026. These regulatory milestones are critical for entering the U.S. and European markets, which represent significant revenue opportunities. Success in these regions could substantially increase the company's addressable market and accelerate procedure growth. For investors, the progress toward regulatory approvals and the expanding global footprint signal potential for continued revenue growth and market share gains.
The company's news and updates are available in its newsroom at https://ibn.fm/SSII, and the original release can be viewed on www.newmediawire.com. As with any investment, it is important to review the full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.
